Allergic Rhinitis
Respiratory 1 original drugsMarket Leaders
Phase 3 Readouts Pro
6 active Phase 3 trials with confidence-graded completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Treatments by Mechanism
Top 9 mechanisms across 20 industry trials with a known mechanism of action.
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Clinical Pipeline by Phase
266 industry-sponsored trials across 115 sponsors
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Viatris Inc. | Treatment with 137 µg azelastine hydrochloride and 50 μg of fluticasone propionate | — | NOT YET RECRUITING | 2027-03 | NCT07597473 |
| MEDA Pharma GmbH & Co. KG | Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 3 | — | COMPLETED | 2021-12-04 | NCT04652245 |
| Bayer | Loratadine (Claritin, BAY76-2211) | — | COMPLETED | 2019-11-13 | NCT04162795 |
| MEDA Pharma GmbH & Co. KG | Azelastine hydrochloride + fluticasone propionate nasal spray | — | COMPLETED | 2017-03-29 | NCT03004131 |
| ALK-Abelló A/S | Grazax | — | COMPLETED | 2015-12 | NCT01854736 |
| Menarini International Operations Luxembourg SA | Bilastine | — | COMPLETED | 2015-12 | NCT02576041 |
| Meda Pharmaceuticals | 205.5 mcg of azelastine hydrochloride | — | COMPLETED | 2014-04 | NCT01880840 |
| HAL Allergy | PURETHAL Birch, 20.000 AUM/ml | — | COMPLETED | 2014-02 | NCT01918956 |
| Sumitomo Pharma America, Inc. | ciclesonide nasal aerosol | — | COMPLETED | 2013-07 | NCT01654536 |
| Handok Inc. | Ciclesonide | Glucocorticoid receptor | COMPLETED | 2012-07 | NCT01430260 |
| ORA, Inc. | Fluticasone Propionate Nasal Spray | — | COMPLETED | 2011-10 | NCT01439815 |
| Reig Jofre Group | — | — | COMPLETED | 2011-06 | NCT01478425 |
| Alcon Research | Olopatadine hydrochloride 0.6% nasal spray (PATANASE) | — | COMPLETED | 2011-01 | NCT00789555 |
| HAL Allergy | PURETHAL Grasses, 20.000 AUM/ml | — | COMPLETED | 2010-09 | NCT01059266 |
| Alcon Research | Olopatadine HCl Nasal Spray, 0.6% | — | COMPLETED | 2009-05 | NCT00845195 |
| Alcon Research | Olopatadine HCL Nasal Spray, 0.6% | — | COMPLETED | 2009-01 | NCT00691665 |
| Merck | loratadine | — | COMPLETED | 2008-12 | NCT00730912 |
| Alcon Research | Olopatadine 0.6% / Azelastine 137 mcg | — | COMPLETED | 2008-11 | NCT00772304 |
| UCB Pharma | levocetirizine dihydrochloride | — | COMPLETED | 2008-07 | NCT00653224 |
| UCB Pharma | levocetirizine dihydrochloride | — | COMPLETED | 2008-06 | NCT00621959 |
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| ALK-Abelló A/S | HDM SLIT-tablet (12 SQ-HDM) | — | RECRUITING | 2026-07 | NCT07060885 |
| Daewon Pharmaceutical Co., Ltd. | Experimental | — | RECRUITING | 2026-08-31 | NCT07168473 |
| Eli Lilly | LY3650150 | — | RECRUITING | 2026-09 | NCT06339008 |
| Genrix (Shanghai) Biopharmaceutical Co., Ltd. | GR1802 injection | — | RECRUITING | 2026-04-30 | NCT07154342 |
| Shanghai Mabgeek Biotech.Co.Ltd | MG-K10 Humanized Monoclonal Antibody Injection | — | RECRUITING | 2025-05-31 | NCT06846385 |
| Laboratorios Silanes S.A. de C.V. | Desloratadine / Betamethasone in fixed dose | — | RECRUITING | 2025-05-11 | NCT06916884 |
| Longbio Pharma | LP-003 | — | ACTIVE NOT RECRUITING | 2026-03-31 | NCT07291284 |
| Inmunotek S.L. | 3,000 MM09 | — | NOT YET RECRUITING | 2026-06-01 | NCT05641272 |
| Prime Gene Therapeutics Co., Ltd. | PG-011 nasal spray 0.6%(twice daily) | — | NOT YET RECRUITING | 2026-06-30 | NCT07146126 |
| Genrix (Shanghai) Biopharmaceutical Co., Ltd. | GR1802 injection | — | NOT YET RECRUITING | 2027-05-15 | NCT07199257 |
| EMS | DEP114 | — | NOT YET RECRUITING | 2025-03-15 | NCT06272409 |
| Eurofarma Laboratorios S.A. | Desloratadine , Prednisolone | — | COMPLETED | 2025-03-23 | NCT05214911 |
| Keymed Biosciences Co.Ltd | CM310 | — | COMPLETED | 2023-12-04 | NCT05908032 |
| Allergy Therapeutics | PQ Grass | — | COMPLETED | 2023-11-01 | NCT05540717 |
| Novartis | Mometasone | — | COMPLETED | 2023-06-20 | NCT05311475 |
| Novartis | — | — | COMPLETED | 2023-06-14 | NCT05590598 |
| ALK-Abelló A/S | Sublingual allergy immunotherapy tablet | — | COMPLETED | 2023-04-01 | NCT04145219 |
| Opella Healthcare Group SAS, a Sanofi Company | Fexofenadine | — | COMPLETED | 2023-03-14 | NCT05692154 |
| Abdi Ibrahim Ilac San. ve Tic A.S. | AI201901 | — | COMPLETED | 2023-03-03 | NCT04729517 |
| ALK-Abelló A/S | HDM SLIT-tablet | — | COMPLETED | 2022-05-18 | NCT03654976 |
| Regeneron | REGN5713 | — | COMPLETED | 2021-08-24 | NCT04709575 |
| ALK-Abelló A/S | HDM SLIT-tablet | — | COMPLETED | 2021-04-24 | NCT04541004 |
| Bayer | Azelastine hydrochloride (BAYR9258) | — | COMPLETED | 2021-03-17 | NCT04264637 |
| Libbs Farmacêutica LTDA | Fluticasone Propionate | Beta-2 adrenergic receptor/Glucocorticoid receptor | COMPLETED | 2020-04-01 | NCT04332978 |
| MEDA Pharma GmbH & Co. KG | Azelastine Hydrochl./Fluticasone Prop. 0.137/0.05 MG/ACTUAT | — | COMPLETED | 2019-09-24 | NCT03599791 |
| Hanmi Pharmaceutical Company Limited | HCP1102 | — | COMPLETED | 2019-06-24 | NCT04324918 |
| Marinomed Biotech AG | Rhinocort | Corticosteroid [EPC] | COMPLETED | 2019-04-05 | NCT03755557 |
| Glenmark Specialty S.A. | GSP 301 NS | — | COMPLETED | 2018-11-14 | NCT03463031 |
| Leti Pharma GmbH | s.c. injection | — | COMPLETED | 2018-07-30 | NCT01694836 |
| Novartis | Omalizumab | Anti-IgE [EPC] | COMPLETED | 2018-05-11 | NCT03369704 |
| Glenmark Specialty S.A. | GSP 301 NS | — | COMPLETED | 2017-07 | NCT02709538 |
| Hanlim Pharm. Co., Ltd. | HL151 | — | COMPLETED | 2017-02-20 | NCT03655210 |
| Glenmark Specialty S.A. | GSP 301 NS | — | COMPLETED | 2017-01 | NCT02870205 |
| BioTech Tools S.A. | gpASIT+TM | — | COMPLETED | 2016-08 | NCT02560948 |
| Glenmark Specialty S.A. | GSP 301 NS | — | COMPLETED | 2016-07 | NCT02631551 |
| ALK-Abelló A/S | Grazax | — | COMPLETED | 2015-09 | NCT01061203 |
| Hanmi Pharmaceutical Company Limited | HCP1102+HGP0711Placebo | — | COMPLETED | 2015-07 | NCT02552667 |
| Organon and Co | Desloratadine 5 mg | — | COMPLETED | 2015-04-27 | NCT02320396 |
| Abbott | Phleum pratense grass pollen allergen extract | — | COMPLETED | 2015-03 | NCT02245360 |
| Padagis LLC | Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray | — | COMPLETED | 2015-02 | NCT02230696 |
| Ahn-Gook Pharmaceuticals Co.,Ltd | AGR tablet | — | COMPLETED | 2015-01 | NCT01982916 |
| AstraZeneca | Ciclesonide | Glucocorticoid receptor | COMPLETED | 2014-10 | NCT02155881 |
| EMS | Dexchlorpheniramine + Betamethasone | — | COMPLETED | 2014-10 | NCT01529229 |
| Amneal Pharmaceuticals, LLC | Mometasone Furoate Nasal Spray, 50 mcg | — | COMPLETED | 2014-03 | NCT02125253 |
| Meda Pharmaceuticals | azelastine hydrochloride and fluticasone propionate | Glucocorticoid receptor/Histamine H1 receptor | COMPLETED | 2014-02 | NCT01915823 |
| Organon and Co | Desloratadine 5 mg | — | COMPLETED | 2014-01-26 | NCT01918033 |
| Organon and Co | Montelukast Oral Granules (OG) | — | COMPLETED | 2013-12-24 | NCT01852812 |
| Tanabe Pharma Corporation | Bepotastine besilate | H1-receptor | COMPLETED | 2013-12 | NCT01861522 |
| Actavis Inc. | Mometasone Nasal Spray | — | COMPLETED | 2013-12 | NCT01850823 |
| Tanabe Pharma Corporation | Bepotastine besilate | H1-receptor | COMPLETED | 2013-11 | NCT01900054 |
| Meda Pharmaceuticals | Dymista Nasal Spray | — | COMPLETED | 2013-11 | NCT01794741 |
| Teva Branded Pharmaceutical Products R&D, Inc. | BDP Nasal Aerosol | — | COMPLETED | 2013-10 | NCT01783548 |
| Organon and Co | Montelukast | — | COMPLETED | 2013-09-01 | NCT01857063 |
| Nasaleze International Ltd | — | — | COMPLETED | 2013-06 | NCT03039816 |
| Yuhan Corporation | Bilastine | — | COMPLETED | 2013-06 | NCT01400828 |
| ALK-Abelló A/S | AVANZ olea | — | COMPLETED | 2013-04 | NCT01674595 |
| Sumitomo Pharma America, Inc. | Ciclesonide nasal aerosol 37 mcg | — | COMPLETED | 2013-03 | NCT01458275 |
| Eurofarma Laboratorios S.A. | Mometasone furoate | H1 receptor | COMPLETED | 2013-02 | NCT01372865 |
| Teva Branded Pharmaceutical Products R&D, Inc. | BDP | — | COMPLETED | 2013-02 | NCT01697956 |
| GSK | Fluticasone propionate | Beta-2 adrenergic receptor/Glucocorticoid receptor | COMPLETED | 2013-02 | NCT01817790 |
| Hanmi Pharmaceutical Company Limited | Montelukast + Levocetirizine | — | COMPLETED | 2013-02 | NCT01640535 |
| Laboratorios Leti, S.L. | Allergen extract (Phleum pratense) | — | COMPLETED | 2013-01 | NCT00916422 |
| Sumitomo Pharma America, Inc. | Ciclesonide nasal aerosol 37 mcg | — | COMPLETED | 2012-12 | NCT01451541 |
| Organon and Co | Montelukast 10 mg/loratadine 10 mg | — | COMPLETED | 2012-10-10 | NCT01673620 |
| Padagis LLC | Mometasone furoate | H1 receptor | COMPLETED | 2012-10 | NCT01673659 |
| InQpharm Group | — | — | COMPLETED | 2012-09 | NCT01503957 |
| ALK-Abelló A/S | AVANZ MITE | — | COMPLETED | 2012-07 | NCT01568190 |
| Stallergenes Greer | Birch pollen allergen extract | — | COMPLETED | 2012-07 | NCT01731249 |
| Bayer | Phenylephrine HCl (Sinus Comfort, BAY112476) | — | COMPLETED | 2012-06-06 | NCT04534452 |
| Azidus Brasil | Cloratadd-D | — | COMPLETED | 2012-04 | NCT01228630 |
| Idorsia Pharmaceuticals Ltd. | ACT-129968 | — | COMPLETED | 2012-02 | NCT01484119 |
| ALK-Abelló A/S | Pangramin SLIT HDM mix. | — | COMPLETED | 2012-02 | NCT01603056 |
| GenMont Biotech Incorporation | eN-Lac® | — | COMPLETED | 2012-01 | NCT01116778 |
| Tanabe Pharma Corporation | TAU-284 | — | COMPLETED | 2011-12 | NCT01425632 |
| Hanlim Pharm. Co., Ltd. | mometasone furoate plus azelastine HCl | — | COMPLETED | 2011-12 | NCT01470053 |
| Sumitomo Pharma America, Inc. | ciclesonide nasal aerosol | — | COMPLETED | 2011-11 | NCT01378429 |
| Sumitomo Pharma America, Inc. | ciclesonide | Glucocorticoid receptor | COMPLETED | 2011-11 | NCT01401465 |
| Bayer | Phenylephrine | — | COMPLETED | 2011-10 | NCT01413958 |
| Apotex Inc. | Ciclesonide nasal spray, 50 μg per actuation. | — | COMPLETED | 2011-08 | NCT02273817 |
| SamA Pharmaceutical Co., Ltd | CITUS Dry Syrup | — | COMPLETED | 2011-08 | NCT01539304 |
| Teva Branded Pharmaceutical Products R&D, Inc. | BDP HFA | — | COMPLETED | 2011-07 | NCT01307319 |
| Magna Pharmaceuticals, Inc. | STAHIST | — | COMPLETED | 2011-06 | NCT01293201 |
| Sumitomo Pharma America, Inc. | ciclesonide hydrofluoroalkane (HFA) nasal aerosol | — | COMPLETED | 2011-04 | NCT01287364 |
| Meda Pharmaceuticals | Azelastine hydrochloride nasal spray 0.15% | — | COMPLETED | 2011-04 | NCT01018862 |
| Sumitomo Pharma America, Inc. | ciclesonide HFA 160 μg | — | COMPLETED | 2010-11 | NCT01067105 |
| Teva Branded Pharmaceutical Products R&D, Inc. | Prednisone capsules | — | COMPLETED | 2010-09 | NCT01133626 |
| GSK | fluticasone furoate nasal spray | — | COMPLETED | 2010-05 | NCT01231464 |
| Sumitomo Pharma America, Inc. | Ciclesonide HFA Nasal Aerosol 320 mcg | — | COMPLETED | 2010-05 | NCT01033825 |
| Teva Branded Pharmaceutical Products R&D, Inc. | Beclomethasone dipropionate | Glucocorticoid receptor | COMPLETED | 2010-02-28 | NCT01024608 |
| Eurofarma Laboratorios S.A. | Noex | — | COMPLETED | 2010-02 | NCT01022047 |
| Sumitomo Pharma America, Inc. | Ciclesonide HFA 160 μg | — | COMPLETED | 2010-02 | NCT01010971 |
| Sumitomo Pharma America, Inc. | Ciclesonide HFA 80 mcg | — | COMPLETED | 2010-01 | NCT00953147 |
| Clinical Research International Limited | Levocetirizine | — | COMPLETED | 2010-01 | NCT01000792 |
| Bayer | Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg | — | COMPLETED | 2009-11 | NCT00976209 |
| Roxall Medizin | Subcutaneous injections with highly polymerized allergen extract | — | COMPLETED | 2009-11 | NCT01012531 |
| Stallergenes Greer | 300 IR | — | COMPLETED | 2009-08 | NCT00955825 |
| Meda Pharmaceuticals | azelastineHcl | — | COMPLETED | 2009-07 | NCT00883168 |
| Organon and Co | Mometasone furoate nasal spray (MFNS) | — | COMPLETED | 2009-05 | NCT00599027 |
| Sumitomo Pharma America, Inc. | 80 mcg Ciclesonide | — | COMPLETED | 2009-02 | NCT00790023 |
| Meda Pharmaceuticals | 0.15% azelastine hydrochloride | — | COMPLETED | 2009-02 | NCT00824473 |
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | TQH2722 injection | — | RECRUITING | 2026-11 | NCT07398859 |
| Alixer Nexgen Therapeutics Limited | ALDP001 Nasal Spray | — | RECRUITING | 2026-04 | NCT07219849 |
| Keymed Biosciences Co.Ltd | Stapokibart Injection | — | RECRUITING | 2025-10-30 | NCT06525597 |
| Guangdong Hengrui Pharmaceutical Co., Ltd | SHR-1819 Injection | — | RECRUITING | 2025-10 | NCT07091357 |
| Prime Gene Therapeutics Co., Ltd. | Pumecitinib Nasal Spray 0.3% | — | ACTIVE NOT RECRUITING | 2025-05-15 | NCT06837233 |
| Genrix (Shanghai) Biopharmaceutical Co., Ltd. | GR1802 injection | — | ACTIVE NOT RECRUITING | 2025-05 | NCT06315426 |
| Akeso | AK139 | — | NOT YET RECRUITING | 2026-09-30 | NCT07436234 |
| Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | Sublingual Film for Dermatophagoides pteronyssinus | — | NOT YET RECRUITING | 2027-06-01 | NCT07475715 |
| Jemincare | JYB1904 | — | NOT YET RECRUITING | 2027-10 | NCT07459452 |
| Inimmune Corporation | INI-2004 | — | COMPLETED | 2026-04-23 | NCT07556393 |
| RDC Clinical Pty Ltd | — | — | COMPLETED | 2026-01-29 | NCT06907680 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | TQC2938 injection | — | COMPLETED | 2025-09-12 | NCT07052097 |
| Shanghai JunTop Biosciences Co., LTD | JT002 Nasal spray | — | COMPLETED | 2025-05-06 | NCT06861101 |
| Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | TQH2722 injection | — | COMPLETED | 2025-04-30 | NCT06760182 |
| MEDA Pharma GmbH & Co. KG | Treatment A: Azelastine hydrochloride 0.15% nasal spray (Azelair) | — | COMPLETED | 2024-02-23 | NCT06126952 |
| Keymed Biosciences Co.Ltd | CM310 | — | COMPLETED | 2023-12-10 | NCT05908721 |
| Longbio Pharma | LP-003 dose 1 | — | COMPLETED | 2023-10-19 | NCT06046391 |
| Regeneron | REGN5713 | — | COMPLETED | 2023-07-31 | NCT05430919 |
| Revolo Biotherapeutics | IRL201104 | — | COMPLETED | 2023-03-27 | NCT05098522 |
| Anhui Palo Alto Pharmaceuticals, Inc. | PA9159 nasal spray solution, 10 μg once daily for 14 days | — | COMPLETED | 2022-10-10 | NCT05234580 |
| AllerPops Corp | — | — | COMPLETED | 2022-09-05 | NCT05956691 |
| Synmosa Biopharma Corp. | azelastine/fluticasone 137/50 mcg nasal spray | — | COMPLETED | 2021-07-20 | NCT06051786 |
| Marinomed Biotech AG | Eye Drops, Solution in Single-Dose Container | — | COMPLETED | 2021-05-27 | NCT04532710 |
| Humanis Saglık Anonim Sirketi | 140/100 μg Azelastine hydrochloride/Beclomethasone Dipropionate) | — | COMPLETED | 2021-04-10 | NCT04817800 |
| Advagene Biopharma Co. Ltd. | AD17002 | — | COMPLETED | 2020-07-30 | NCT04088721 |
| Emergo Therapeutics, Inc. | Norketotifen | — | COMPLETED | 2019-05-18 | NCT03887026 |
| Regeneron | Dupilumab | Interleukin-4 Receptor alpha Antagonist [EPC] | COMPLETED | 2019-05-14 | NCT03558997 |
| AOBiome LLC | B244 suspension | — | COMPLETED | 2018-12-21 | NCT03290248 |
| Anergis | AllerT | — | COMPLETED | 2017-07 | NCT02943720 |
| HAL Allergy | SUBLIVAC FIX Phleum Prat. | — | COMPLETED | 2016-10 | NCT02556801 |
| Allergy Therapeutics | Grass MATA MPL (0.5ml) 5100SU | — | COMPLETED | 2016-05-05 | NCT02582073 |
| 3E Therapeutics Corporation | Nasapaque Nasal Solution | — | COMPLETED | 2015-07 | NCT02377895 |
| Circassia Limited | Grass-SPIRE | — | COMPLETED | 2015-03 | NCT02161107 |
| Glenmark Pharmaceuticals Ltd. India | GSP 301-1 NS (QD) | — | COMPLETED | 2015-02 | NCT02318303 |
| Sun Pharma Advanced Research Company Limited | SPARC1310 I | — | COMPLETED | 2014-12 | NCT01940146 |
| Circassia Limited | Ragweed-SPIRE | — | COMPLETED | 2014-10 | NCT02061709 |
| Circassia Limited | Ragweed-SPIRE | — | COMPLETED | 2014-10 | NCT02061670 |
| GSK | GSK2245035 | — | COMPLETED | 2014-08 | NCT01788813 |
| Glenmark Pharmaceuticals Ltd. India | Molo 1 (also referred as GSP 301-2 NS) | — | COMPLETED | 2014-02-28 | NCT03444506 |
| Ono Pharmaceutical Co., Ltd. | Cetirizine | — | COMPLETED | 2014-02 | NCT01748344 |
| Laboratorios Leti, S.L. | Prick test Dermatophagoides pteronyssinus allergen extract | — | COMPLETED | 2014-01 | NCT01821716 |
| BioTech Tools S.A. | gpASIT+TM | — | COMPLETED | 2013-12 | NCT02156791 |
| Novartis | QAW039 | — | COMPLETED | 2013-10 | NCT01804400 |
| Anergis | AllerT low dose | — | COMPLETED | 2013-09 | NCT01720251 |
| ALK-Abelló A/S | SLITone ULTRA HDM immunotherapy | — | COMPLETED | 2013-08 | NCT01728298 |
| HAL Allergy | SUBLIVAC FIX phleum prat. | — | COMPLETED | 2013-05 | NCT01682070 |
| HAL Allergy | PURETHAL Mites 6,667 AU/ml | — | COMPLETED | 2013-05 | NCT01438463 |
| Leti Pharma GmbH | Depigoid Phleum | — | COMPLETED | 2013-04 | NCT01634958 |
| HAL Allergy | SUBLIVAC FIX Birch | — | COMPLETED | 2013-03 | NCT01639768 |
| Bausch & Lomb Incorporated | Bepotastine besilate | H1-receptor | COMPLETED | 2013-02 | NCT01753739 |
| BioTech Tools S.A. | gpASIT+TM | — | COMPLETED | 2013-01 | NCT01506375 |
| Sun Pharma Advanced Research Company Limited | SPARC1203 | — | COMPLETED | 2012-11 | NCT01614691 |
| Shionogi | S-555739 Dose 1 | — | COMPLETED | 2012-11 | NCT01651871 |
| Bausch & Lomb Incorporated | Bepotastine besilate formulation | — | COMPLETED | 2012-08 | NCT01578278 |
| Stallergenes Greer | 100 IR house dust mites allergen extract tablet | — | COMPLETED | 2012-03 | NCT01527188 |
| Teva Pharmaceuticals USA | Mometasone furoate | H1 receptor | COMPLETED | 2012-01 | NCT01523236 |
| Novartis | VAK694; Alutard Avanz SQ | — | COMPLETED | 2011-10 | NCT01018693 |
| BioTech Tools S.A. | gpASIT+TM | — | COMPLETED | 2011-10 | NCT01308021 |
| Palau Pharma S.L.U. | UR-63325 | — | COMPLETED | 2011-03 | NCT01260753 |
| Novartis | VAK694 | — | COMPLETED | 2011-02 | NCT00929968 |
| Bausch & Lomb Incorporated | Bepotastine Besilate Nasal Spray 2% Twice a day | — | COMPLETED | 2011-02 | NCT01277341 |
| Idorsia Pharmaceuticals Ltd. | ACT-129968 | — | COMPLETED | 2011-02 | NCT01241214 |
| Leti Pharma GmbH | Allergoid, allergenic extract of 100% Birch | — | COMPLETED | 2011-02 | NCT01144429 |
| AstraZeneca | AZD8848 | — | COMPLETED | 2010-12 | NCT01185080 |
| Respivert Ltd | RV568 | — | COMPLETED | 2010-11 | NCT01230619 |
| Magna Pharmaceuticals, Inc. | STAHIST | — | COMPLETED | 2010-10 | NCT01171664 |
| Nuvo Research GmbH | WF10 | — | COMPLETED | 2010-09 | NCT01586468 |
| Afexa Life Sciences Inc | COLD-fX | — | COMPLETED | 2010-09 | NCT00726401 |
| Bausch & Lomb Incorporated | bepotastine besilate nasal product - low dose | — | COMPLETED | 2010-08 | NCT01222299 |
| HAL Allergy | PURETHAL Mites 20,000 AUeq/ml | — | COMPLETED | 2010-08 | NCT00973453 |
| Novartis | QAV680 + Cetirizine | — | COMPLETED | 2010-07-28 | NCT01103050 |
| Pfizer | PF-03654764 | — | COMPLETED | 2010-05 | NCT01033396 |
| Capnia, Inc. | Nasal CO2 | — | COMPLETED | 2009-10 | NCT00917020 |
| Capnia, Inc. | Nasal CO2 | — | COMPLETED | 2009-10 | NCT00917111 |
| Teva Branded Pharmaceutical Products R&D, Inc. | Beclomethasone dipropionate HFA Nasal Aerosol | — | COMPLETED | 2009-05 | NCT00854360 |
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | JNJ-39220675 | — | COMPLETED | 2009-02 | NCT00804687 |
| Novartis | QAV680 | — | COMPLETED | 2008-12 | NCT00784732 |
| Dart NeuroScience, LLC | BLX-028914 | — | COMPLETED | 2008-12 | NCT00758446 |
| Alcon Research | Olopatadine Hydrochloride Nasal Spray 0.6% | — | COMPLETED | 2008-12 | NCT00794144 |
| Capnia, Inc. | Nasal CO2 | — | COMPLETED | 2008-10 | NCT00688441 |
| GSK | GSK1004723 (200mg) | — | COMPLETED | 2008-08 | NCT00824356 |
| Merck | SCH 900538 | — | COMPLETED | 2008-07 | NCT00673062 |
| Oxagen Ltd | OC000459 | — | COMPLETED | 2008-07 | NCT00697281 |
| Ligand Pharmaceuticals | Budesonide + Azelastine | — | COMPLETED | 2008-05 | NCT00940953 |
| GSK | GSK256066 | — | COMPLETED | 2008-05 | NCT00612118 |
| Capnia, Inc. | Nasal Carbon Dioxide | — | COMPLETED | 2008-05 | NCT00638755 |
| Max Zeller Soehne AG | Desloratadin | — | COMPLETED | 2008-04 | NCT00862225 |
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | JNJ-17166864 | — | COMPLETED | 2008-02 | NCT00604123 |
| Laboratorios Leti, S.L. | Depigoid® (500 DPP/ml) | — | TERMINATED | 2012-07 | NCT01591343 |
| Anergis | AllerT SC | — | TERMINATED | 2009-03 | NCT01728519 |
| ALK-Abelló A/S | OSIRIS | — | TERMINATED | — | NCT01240954 |
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| AJU Pharm Co., Ltd. | AJU-R713 | — | NOT YET RECRUITING | 2025-12 | NCT07231861 |
| Anhui Palo Alto Pharmaceuticals, Inc. | PA9159 nasal spray solution, 80 μg one day treatment | — | COMPLETED | 2025-06-09 | NCT07345442 |
| Inimmune Corporation | INI-2004 | — | COMPLETED | 2024-09-05 | NCT06038279 |
| Humanis Saglık Anonim Sirketi | Azelastine Hydrochloride/ Fluticasone propionate nasal spray | — | COMPLETED | 2023-04-26 | NCT06180083 |
| H. Lundbeck A/S | Lu AG09222 | — | COMPLETED | 2022-07-12 | NCT05126316 |
| Anhui Palo Alto Pharmaceuticals, Inc. | PA9159 nasal spray solution, 10 μg one day treatment | — | COMPLETED | 2022-01-05 | NCT05170763 |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | CSPCHA115 100 mg; Matching placebo 100 mg | — | COMPLETED | 2020-06-01 | NCT04161547 |
| Tanabe Pharma Corporation | MT-2990 | — | COMPLETED | 2018-12-27 | NCT03570957 |
| Allergy Therapeutics | Grass MATA MPL | — | COMPLETED | 2017-04-27 | NCT03931993 |
| Allergy Therapeutics | Grass MATA MPL 10200 | — | COMPLETED | 2015-10 | NCT02557633 |
| Xencor, Inc. | XmAb7195 | — | COMPLETED | 2015-09-21 | NCT02148744 |
| Merck | MK-8237 | — | COMPLETED | 2015-07-20 | NCT01852825 |
| Pfizer | IGE-1 | — | COMPLETED | 2015-06 | NCT01723254 |
| Immunomic Therapeutics, Inc. | CryJ2-DNA-LAMP plasmid vaccine by intradermal injection | — | COMPLETED | 2015-03 | NCT02146781 |
| Johnson & Johnson | Esketamine | — | COMPLETED | 2014-10 | NCT02154334 |
| PharmaKing | Montelukast | — | COMPLETED | 2014-01 | NCT02029313 |
| Mylan Pharmaceuticals Inc | Mometasone Furoate Monohydrate Nasal Spray, 50 μg/act. | — | COMPLETED | 2013-10 | NCT02109185 |
| Stallergenes Greer | 500 IR house dust mites allergen extract tablet | — | COMPLETED | 2013-09 | NCT01919554 |
| MedImmune LLC | Omalizumab | Anti-IgE [EPC] | COMPLETED | 2013-06 | NCT01544348 |
| Sumitomo Pharma America, Inc. | ciclesonide nasal aerosol | — | COMPLETED | 2011-08 | NCT01371786 |
| Roche | MEMP1972A | — | COMPLETED | 2011-04 | NCT01160861 |
| MEDA Pharma GmbH & Co. KG | Azelastine, Fluticasone | — | COMPLETED | 2010-10 | NCT01194622 |
| MEDA Pharma GmbH & Co. KG | Azelastine, Fluticasone | — | COMPLETED | 2010-10 | NCT01190852 |
| Gilead | CAL-263 | — | COMPLETED | 2010-04 | NCT01066611 |
| Pfizer | Ibuprofen | Nonsteroidal Anti-inflammatory Drug [EPC] | COMPLETED | 2010-04 | NCT01064726 |
| Procter and Gamble | Doxylamine Succinate USP | — | COMPLETED | 2009-06 | NCT00796315 |
| Merck | prednisone | Corticosteroid [EPC] | COMPLETED | 2009-05-07 | NCT00828061 |
| Teva Branded Pharmaceutical Products R&D, Inc. | BDP HFA Nasal Aerosol | — | COMPLETED | 2009-04 | NCT01537692 |
| Gilead | CAL-101 | — | COMPLETED | 2009-03 | NCT00836914 |
| AstraZeneca | AZD8848 | — | COMPLETED | 2009-03 | NCT00770003 |
| Johnson & Johnson Consumer and Personal Products Worldwide | diphenhydramine HCl | — | COMPLETED | 2008-11 | NCT00762749 |
| AstraZeneca | AZD8848 | — | COMPLETED | 2008-05 | NCT00688779 |
| Anergis | Histamine | — | COMPLETED | 2008-03 | NCT01719133 |
| Sumitomo Pharma Co., Ltd. | DSP-3025 | — | COMPLETED | — | NCT00925678 |
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | JNJ38224342 | — | COMPLETED | — | NCT01054352 |
| Novartis | Mometasone + Azelastine | — | TERMINATED | 2023-09-08 | NCT05887843 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | TQC3564 tablets | — | TERMINATED | 2023-05-09 | NCT05607446 |
| Woodmont Pharmaceuticals, Inc. | Dose Level 1 | — | TERMINATED | 2017-04-29 | NCT03038971 |
Novel Drugs by Company (New molecular entities)
Reformulations (9 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
Generic Drugs (9 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs